MannKind (MNKD) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free MNKD Stock Alerts $4.67 +0.17 (+3.78%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 2:48 PM | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationMay 29 at 9:47 AM | markets.businessinsider.comPulmatrix Enters Cross License Agreement With MannKind - Quick FactsMay 29 at 8:45 AM | prnewswire.comPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationMay 29 at 8:45 AM | globenewswire.comMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixMay 23, 2024 | wsj.comMannKind Corp.May 22, 2024 | insidertrades.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells $109,682.42 in StockMay 21, 2024 | marketbeat.comDavid Thomson Sells 23,537 Shares of MannKind Co. (NASDAQ:MNKD) StockMannKind Co. (NASDAQ:MNKD - Get Free Report) EVP David Thomson sold 23,537 shares of the business's stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $4.66, for a total transaction of $109,682.42. Following the sale, the executive vice president now directly owns 873,616 shares of the company's stock, valued at $4,071,050.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.May 15, 2024 | insidertrades.comSteven B. Binder Sells 3,618 Shares of MannKind Co. (NASDAQ:MNKD) StockMay 14, 2024 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells 3,618 Shares of StockMannKind Co. (NASDAQ:MNKD - Get Free Report) EVP Steven B. Binder sold 3,618 shares of the company's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $4.31, for a total value of $15,593.58. Following the transaction, the executive vice president now owns 845,967 shares of the company's stock, valued at $3,646,117.77. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.May 10, 2024 | markets.businessinsider.comMannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical DevelopmentsMay 10, 2024 | finance.yahoo.comMannKind First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Forecasted to Post Q2 2024 Earnings of $0.00 Per ShareMannKind Co. (NASDAQ:MNKD - Free Report) - Leerink Partnrs dropped their Q2 2024 earnings estimates for MannKind in a report released on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their pMay 10, 2024 | finance.yahoo.comMannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...May 9, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Given Overweight Rating at Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating and issued a $6.50 price objective on shares of MannKind in a report on Thursday.May 9, 2024 | finance.yahoo.comShareholders May Not Be So Generous With MannKind Corporation's (NASDAQ:MNKD) CEO Compensation And Here's WhyMay 8, 2024 | msn.comMNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSMannKind (NASDAQ:MNKD - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.02. The firm had revenue of $66.26 million for the quarter, compared to analyst estimates of $60.55 million. The firm's quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) EPS.May 8, 2024 | markets.businessinsider.comMannKind Corp. Q1 Earnings SummaryMay 8, 2024 | globenewswire.comMannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateMay 6, 2024 | finance.yahoo.comMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMay 6, 2024 | globenewswire.comMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseMay 2, 2024 | marketbeat.comMannKind (MNKD) Set to Announce Earnings on WednesdayMannKind (NASDAQ:MNKD) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 1, 2024 | globenewswire.comMannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024April 30, 2024 | globenewswire.comMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesApril 29, 2024 | marketwatch.comMannKind Gets FDA Clearance for Clofazimine IND ApplicationApril 29, 2024 | markets.businessinsider.comMannKind Gets FDA Nod For Phase 3 Study Of Clofazimine Inhalation Suspension For NTM Lung DiseaseApril 29, 2024 | msn.comMannKind rises as FDA advances rare lung disease therapy to Phase 3 trialApril 29, 2024 | globenewswire.comMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseApril 5, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 4.9%MannKind (NASDAQ:MNKD) Trading Up 4.9%April 3, 2024 | globenewswire.comMannKind Repays Certain Debt ObligationsApril 1, 2024 | finance.yahoo.comMannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returnsMarch 30, 2024 | nasdaq.comMay 10th Options Now Available For MannKind (MNKD)March 28, 2024 | uk.investing.comMannKind CFO Steven Binder to retire, Chris Prentiss to take overMarch 27, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Trading Down 3.9%MannKind (NASDAQ:MNKD) Shares Down 3.9%March 26, 2024 | globenewswire.comMannKind Announces CFO TransitionMarch 25, 2024 | finance.yahoo.comJim Cramer Says You Should Avoid These 11 StocksMarch 22, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Up 3.6%MannKind (NASDAQ:MNKD) Trading Up 3.6%March 18, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Receives "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and set a $6.50 target price on shares of MannKind in a research report on Friday.March 17, 2024 | finance.yahoo.comMNKD Mar 2024 5.000 putMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.000 callMarch 16, 2024 | finance.yahoo.comMNKD Mar 2024 4.500 putMarch 11, 2024 | msn.comWhat's Going On With MannKind Stock?March 11, 2024 | marketbeat.comMannKind (NASDAQ:MNKD) Shares Down 4.9% MannKind (NASDAQ:MNKD) Trading Down 4.9%March 11, 2024 | finance.yahoo.comINHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 11, 2024 | globenewswire.comINHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsMarch 10, 2024 | finance.yahoo.comMNKD Mar 2024 6.500 callMarch 9, 2024 | finance.yahoo.comMNKD Mar 2024 3.000 putMarch 8, 2024 | finance.yahoo.comMNKD Mar 2024 3.500 putMarch 5, 2024 | globenewswire.comMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. MNKD Media Mentions By Week MNKD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNKD News Sentiment▼0.770.76▲Average Medical News Sentiment MNKD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNKD Articles This Week▼53▲MNKD Articles Average Week Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Phibro Animal Health News AnaptysBio News Radius Recycling News Omeros News Gossamer Bio News Cara Therapeutics News VBI Vaccines News Madrigal Pharmaceuticals News Alkermes News Amicus Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNKD) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
